Roundup Property Owner Lawsuit Alleges Weedkiller Caused Diffuse B-Cell Non-Hodgkin’s Lymphoma

A Louisiana property owner indicates that he developed stage 4 diffuse B-cell non-Hodgkins lymphoma following use of Roundup, according to a product liability lawsuit filed earlier this week against Monsanto for failing to warn about the risks associated with the widely used weedkiller.

Robert Chaisson filed the complaint (PDF) in the U.S. District Court for the Eastern District of Louisiana on January 14, indicating that he routinely used Roundup on his property for about 25 years before he his cancer diagnosis.

As a result of the injury, Chaisson indicates that he has undergone chemotherapy and other treatments for cancer that could have been avoided if consumers had been warned about the risks associated with the weedkiller, and provided adequate safety instructions.

Learn More About

Roundup Lawsuits

Exposure to RoundUp May Increase Risk of Non-Hodgkins Lymphoma and Other Cancers. Lawsuits Reviewed Nationwide.

Learn More About this Lawsuit See If You Qualify For A Settlement

Monsanto successfully hid the popular weed killer’s link to cancer for years, according to the lawsuit, and Chaisson said he only discovered that his non-Hodgkins lymphoma was caused by Roundup following a 2015 warning issued by the International Agency For Research On Cancer (IARC).

“Plaintiff had no way of knowing about the risk of serious illness associated with the use of and/or exposure to Roundup and glyphosate,” the lawsuit states. “The earliest date one could have learned of the link would have been after IARC released its formal assessment of glyphosate in July 2015.”

Roundup Litigation

Chaisson’s complaint raises allegations that are similar to more than 10,000 other Roundup lawsuits being pursued nationwide, each alleging that Monsanto knew or should have known that Roundup was inherently dangerous and unsafe when used in the manner instructed, yet actively concealed information from consumers and federal regulators.

Given common questions of fact and law raised in the lawsuits, a number of “bellwether” trials are set to go before juries this year, to help lawyers involved in the cases gauge how juries are likely to respond to certain evidence and testimony likely to be repeated throughout the litigation.

In August 2018, the first trial in the country resulted in a $78 million judgment for a former California school groundskeeper, who was granted an early trial date because he is dying from non-Hodgkins lymohoma.

In the federal court system, where all claims have been centralized as part of a multidistrict litigation (MDL) before U.S. District Court Judge Vince Chhabria in the Northern District of California, a series of early trial dates are set to begin late next month. In addition, more than a dozen other claims are set to go to trial in California and Missouri state court throughout 2019.

While the outcomes of these bellwether trials are not binding on Chaisson and other plaintiffs, if Monsanto fails to reach Roundup settlements or otherwise resolve the litigation, hundreds of individual cases may be set for trial in the coming years.


"*" indicates required fields

Share Your Comments

I authorize the above comments be posted on this page*

Have Your Comments Reviewed by a Lawyer

Provide additional contact information if you want an attorney to review your comments and contact you about a potential case. This information will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Bard Argues Hernia Mesh Lawsuits Previously Selected for Bellwether Trials Are No Longer
Bard Argues Hernia Mesh Lawsuits Previously Selected for Bellwether Trials Are No Longer "Representative" (Posted today)

Bard claims two cases selected for the third and fourth bellwether trials are no longer representative of the litigation due to the plaintiffs' worsening injuries and need for additional surgeries due to their failed hernia mesh products.